3月20日 - ** 生物技术公司Windtree Therapeutics WINT.O股价在下午交易中上涨27.8%，至2.16美元
** WINT 表示 (link)，其已与Evofem Biosciences EVFM.PK就其避孕阴道凝胶Phexxi达成许可协议
** WINT将作为Evofem的采购合作伙伴，旨在以更低的成本生产Phexxi
** Co表示，Evofem将保留资产所有权，并继续在美国和国际上推广Phexxi
** 截至最新收盘，WINT在过去12个月下跌了99.4%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.